Evidence map›Paper›PMID 37974956›Full record

ReviewRSC medicinal chemistry2023

The evolution of small molecule enzyme activators.

Louise F Dow, Alfie M Case, Megan P Paustian, Braeden R Pinkerton, Princess Simeon, Paul C Trippier

Open access · greenAbstract readReview
In one paragraph

Review in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Small-molecule allosteric activator of ubiquitin-specific protease 7 (USP7).Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. The role of nicotinamide adenine dinucleotide salvage enzymes in cardioprotection.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2024
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Louise F DowDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center Omaha NE 68106 USA paul.trippier@unmc.edu.
Alfie M CaseDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center Omaha NE 68106 USA paul.trippier@unmc.edu.
Megan P PaustianDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center Omaha NE 68106 USA paul.trippier@unmc.edu.
Braeden R PinkertonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center Omaha NE 68106 USA paul.trippier@unmc.edu.
Princess SimeonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center Omaha NE 68106 USA paul.trippier@unmc.edu.
Paul C TrippierDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center Omaha NE 68106 USA paul.trippier@unmc.edu.ORCID https://orcid.org/0000-0002-4947-5782
Nebraska Medical Center · US

Funding

Development and Characterization of Small Molecule Activators of Peptidase Neurolysin for Stroke TherapyR01NS106879 · NINDS · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI Thomas J Abbruscato, Vardan T. Karamyan · 2018 to 2026
$4.2M
Small Molecule Drug Discovery for CLN3 and CLN6 DiseaseR01HD106590 · NICHD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI TRIPPIER, PAUL · 2021 to 2025
$2.6M
AKR1C Inhibitors as Chemotherapeutic PotentiatorsR01CA226436 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI TRIPPIER, PAUL · 2019 to 2023
$2.0M
UNMC Training Program in Alzheimer’s Disease and Related Dementias Drug DiscoveryT32AG076407 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI HOWARD S FOX, Paul Trippier · 2022 to 2026
$1.1M
NCI NIH HHS R01 CA226436NIA NIH HHS T32 AG076407NICHD NIH HHS R01 HD106590NINDS NIH HHS R01 NS106879
6 · The paper itself

Abstract

There is a myriad of enzymes within the body responsible for maintaining homeostasis by providing the means to convert substrates to products as and when required. Physiological enzymes are tightly controlled by many signaling pathways and their products subsequently control other pathways. Traditionally, most drug discovery efforts focus on identifying enzyme inhibitors, due to upregulation being prevalent in many diseases and the existence of endogenous substrates that can be modified to afford inhibitor compounds. As enzyme downregulation and reduction of endogenous activators are observed in multiple diseases, the identification of small molecules with the ability to activate enzymes has recently entered the medicinal chemistry toolbox to afford chemical probes and potential therapeutics as an alternative means to intervene in diseases. In this review we highlight the progress made in the identification and advancement of non-kinase enzyme activators and their potential in treating various disease states.

Identifiers

PMID37974956
PMCPMC10650962
OpenAlexW4386973510

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.